Cargando…
Activity of enisamium, an isonicotinic acid derivative, against influenza viruses in differentiated normal human bronchial epithelial cells
AIMS: New therapeutics for the control of influenza virus infections are needed to alleviate the burden caused by seasonal epidemics and occasional pandemics, and to overcome the potential risk of drug-resistance emergence. Enisamium iodide (Amizon®, Farmak) is currently approved for clinical use fo...
Autores principales: | Boltz, David, Peng, Xinjian, Muzzio, Miguel, Dash, Pradyot, Thomas, Paul G, Margitich, Victor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6961345/ https://www.ncbi.nlm.nih.gov/pubmed/30466301 http://dx.doi.org/10.1177/2040206618811416 |
Ejemplares similares
-
Enisamium Inhibits SARS-CoV-2 RNA Synthesis
por: Elli, Stefano, et al.
Publicado: (2021) -
Enisamium Reduces Influenza Virus Shedding and Improves Patient Recovery by Inhibiting Viral RNA Polymerase Activity
por: te Velthuis, Aartjan J. W., et al.
Publicado: (2021) -
In Vitro Bioavailability Study of an Antiviral Compound Enisamium Iodide
por: Haltner-Ukomadu, Eleonore, et al.
Publicado: (2018) -
Enisamium is an inhibitor of the SARS-CoV-2 RNA polymerase and shows improvement of recovery in COVID-19 patients in an interim analysis of a clinical trial
por: Holubovska, Olha, et al.
Publicado: (2021) -
Enisamium is a small molecule inhibitor of the influenza A virus and SARS-CoV-2 RNA polymerases
por: Walker, Alexander P, et al.
Publicado: (2020)